In summary, we believe that targeting the ACSS2-PPARD-BCAT1 axis has certain clinical value and can provide a new therapeutic strategy for the comprehensive treatment of pancreatic cancer. This evidence concerns the gene ACSS2 and familial pancreatic carcinoma.